阿托伐他汀对缺血性脑卒中患者血浆基质金属蛋白酶的影响及疗效观察

The effects of atorvastatin on plasma level of matrix metalloproteinases of patients with cerebral ischemic stroke

目的探讨阿托伐他汀对缺血性脑卒中患者血浆基质金属蛋白酶的影响及疗效观察。方法选择80例缺血性脑卒中患者,随机分为观察组和对照组。两组患者均予以降颅压、控制血压血糖、抗凝、改善脑循环等常规对症治疗。观察组在此基础上加用阿托伐他汀20 mg,每天1次,连用2周。结果治疗2周后,两组血浆MMP-3和MMP-9水平均较治疗前明显下降(P<0.05或P<0.01),且观察组下降幅度较对照组更明显(P<0.05)。观察组临床有效率明显高于对照组(χ2=5.54,P<0.05)。结论阿托伐他汀治疗缺血性脑卒中的疗效确切,能明显改善脑梗死部位缺血缺氧和缺损神经功能,其作用机制与降低血浆MMP-3和MMP-9水平有关。

Objective To investigate the effects of atorvastatin on plasma levels of matrix metalloproteinases （MMPs） of patients with cerebral ischemic stroke. Methods Eighty cases of patients with cerebral ischemic stroke were selected and divided into control group and observation group. All patients received common treatment as intracranial decompression, controlling blood pressure and sugar, anticoagu!ation and improving cerebral circulation. Patients in observation group re- ceived extra treatment as taking atorvastatin orally 20 mg qd, for 2 weeks. Results After treatment 2 weeks, the levels of MMP-3 and MMP-9 of both groups descended significantly than pretherapy （P 〈 0.05 or P 〈 0.01 ）. And the change was more obviously in observation group（P 〈 0.05）. Meanwhile, the clinic effective rate of observation group was significantly high- er than that of control group （X^2 =5.54,P 〈 0.05）. Conclusion Treating cerebral ischemic stroke by atorvastatin showes a certain clinic curative effect. Atorvastatin can improve the ischemia and anoxemia of the cerebral infarction area and the function of the defect nerves. Its mechanism of action may related to reducing the plasma levels of MMP-3 and MMP-9.